Rendering

Component: (Network and Table)
Network
2313301 - Disclosure - Income Taxes (Tables)
(http://www.acceleronpharma.com/role/IncomeTaxesTables)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Income Tax Disclosure [Abstract]Period [Axis]
2016-01-01 - 2016-12-31
Income Tax Disclosure [Abstract]
 
Components of the Company's Deferred Tax Assets
The significant components of the Company's deferred tax assets are comprised of the following (in thousands):
 
Year Ended December 31,
 
2016
 
2015
Deferred tax assets:
 
 
 

U.S. and state net operating loss carryforwards
$
109,429

 
$
90,732

Research and development credits
9,717

 
7,864

Deferred revenue
1,666

 
1,883

Accruals and other temporary differences
15,725

 
9,319

Total deferred tax assets
136,537

 
109,798

Less valuation allowance
(136,537
)
 
(109,798
)
Net deferred tax assets
$

 
$

 
 
Schedule of Effective Income Tax Rate Reconciliation
A reconciliation of income tax expense computed at the statutory federal income tax rate to income taxes as reflected in the consolidated financial statements is as follows:
 
Year Ended December 31,
 
2016
 
2015
 
2014
Federal income tax expense at statutory rate
34.0
 %
 
34.0
 %
 
34.0
 %
State income tax, net of federal benefit
5.9
 %
 
4.6
 %
 
4.1
 %
Permanent differences
4.0
 %
 
(8.3
)%
 
2.0
 %
Research and development credit
3.1
 %
 
1.2
 %
 
1.6
 %
Other
(0.1
)%
 
 %
 
4.6
 %
Change in valuation allowance
(46.9
)%
 
(31.5
)%
 
(46.3
)%
Effective income tax rate
 %
 
 %
 
 %